Despite slow process of approvals for new products in the US and a decline in revenues in some of the emerging markets, Dr Reddy's, for the quarter ended June, posted a 14 per cent growth in net ...

Dr Reddy’s to acquire Teva’s product portfolio for US Market The portfolio being acquired is a mix of filed ANDAs pending approval and an approved ANDA.

Operator: Ladies and gentlemen, good day and welcome to the Dr. Reddy's Q1 FY '24 Earnings Call. [Operator Instructions]. I now hand the conference over to Ms. Richa Periwal from Investor ...

Dr. Reddy’s is eyeing double-digit growth in FY24 on the back of its plan to launch around 30 products in the US market. It is also investing in various businesses that may sustain long-term growth.

Dr Reddy's Q3 results: Dr Reddy's gross margin witnessed a 59.2 per cent rise from 53.8 per cent reported in the year-ago period. ... favourable products mix and favourable forex movement which was ...